To examine the effect of individualized starting doses of atorvastatin on achieving target LDL cholesterol, atherogenic lipid profiles and surrogate markers of chronic inflammation in Korean patients with type 2 diabetes. This was an 8-week, multicenter, prospective, open-label, single-step titration trial that enrolled 440 patients with type 2 diabetes to assess the safety and efficacy of patient-tailored atorvastatin therapies (10 mg, 20 mg and 40 mg) based on a patient’s baseline LDL cholesterol levels. Overall, 91% of the patients achieved their LDL cholesterol target at week 8 (94%, 93% and 81% for doses of 10, 20 and 40 mg, respectively). Among those patients who achieved their target goal, over 92% achieved their LDL cholesterol target with the initial dose. There were significant reductions in total cholesterol, triglyceride, non-HDL cholesterol, the total cholesterol to HDL cholesterol ratio and small, dense LDL cholesterol compared to the baseline at week 8 for all of the doses. In addition, high-sensitivity CRP levels were significantly decreased in those patients with baseline high-sensitivity CRP levels over 3 mg/L, whereas adiponectin levels tended to increase for all of the doses at 8 weeks. Atorvastatin was well tolerated at all of the doses throughout the study period. The administration of individualized starting doses of atorvastatin according to baseline LDL cholesterol levels was effective achieving target LDL cholesterol levels and in ameliorating atherogenic lipid profiles and low-grade inflammation in Korean patients with type 2 diabetes.